RMD
ResMed Inc
226.70$
+0.3%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 34.2% | 34.4% | 34.5% | 34.3% | 36.6% | 39.7% | 42.4% | 42.9% | 43.6% | 44.9% | 46.3% | 48.2% | |
| 3.1% | 3.0% | 3.5% | 3.5% | 5.9% | 7.3% | 12.3% | 14.8% | 16.7% | 16.7% | 18.9% | 16.4% | |
| 3.1% | 3.0% | 3.5% | 3.5% | 5.9% | 7.3% | 12.5% | 14.8% | 16.7% | 16.8% | 18.9% | 16.4% | |
| 10.3% | 11.1% | 11.4% | 12.7% | 11.2% | 13.4% | 12.4% | 12.1% | 11.5% | 12.3% | 11.9% | 11.6% | |
| 14.2% | 16.4% | 12.2% | 12.0% | 12.7% | 12.4% | 11.4% | 11.3% | 11.4% | 10.8% | 10.4% | 10.5% | |
| 9.8% | – | – | – | 9.9% | 9.4% | 9.1% | 8.8% | 8.7% | 8.6% | – | – | |
| 41.7% | 41.4% | 41.6% | 41.4% | 40.0% | 39.3% | 37.7% | 37.3% | 36.6% | 35.8% | 34.6% | 37.5% | |
| 8.4% | 7.6% | 7.4% | 7.1% | 6.6% | 6.1% | 5.7% | 5.7% | 5.4% | 5.1% | 4.8% | 5.0% | |
| 36.9% | 35.1% | 32.1% | 29.2% | 28.1% | 26.4% | 26.7% | 27.0% | 26.3% | 25.7% | 26.1% | 26.6% | |
| 11.4% | 11.1% | 11.3% | 13.3% | 12.5% | 11.9% | 12.4% | 12.5% | 15.1% | 14.7% | 15.4% | 15.6% | |
| 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 3.5% | 3.4% | 3.3% | 3.2% | |
| 2.6% | 2.9% | 2.6% | 3.5% | 3.5% | 3.1% | 2.9% | 3.4% | 3.2% | 2.9% | 3.1% | 3.4% | |
| 20.0% | 17.6% | 14.6% | 10.1% | 9.2% | 9.3% | 8.8% | 8.1% | 4.9% | 4.8% | 4.6% | 4.5% | |
| 63.1% | 64.9% | 67.9% | 70.8% | 71.9% | 73.6% | 73.3% | 73.0% | 73.7% | 74.3% | 73.9% | 73.4% | |
| 65.3% | 65.7% | 70.0% | 72.6% | 72.3% | 76.9% | 76.4% | 74.4% | 76.3% | 78.2% | 79.2% | 80.9% | |
| 2.2% | 2.1% | 2.2% | 2.1% | 2.0% | 2.1% | 1.9% | 1.8% | 1.8% | 1.7% | 1.7% | 1.6% |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.